Safety Concerns with Two Classes of Diabetes Drugs

• Autores: Diane S. Aschenbrenner
• Localización: American Journal of Nursing, ISSN 0002-936X, Vol. 116, Nº. 1, 2016, págs. 22-23
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • * Canagliflozin, a sodium–glucose cotransporter-2 inhibitor used to treat type 2 diabetes and marketed under the trade name of Invokana (and Invokamet, which also contains metformin) elevates patients’ risk of bone fractures. There is also an elevated risk of diminished bone mass.

    * All drugs in the class called dipeptidyl peptidase-4 can cause severe and disabling arthralgia (joint pain). The time to onset of arthralgia symptoms has ranged from one day to years after the start of therapy.